3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
7
Myelodysplastic Syndromes
5
Brain Neoplasms
4
Lymphoma
3
Leukemia
3
Glioblastoma
3
Sarcoma
2
Ovarian Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioma
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Refractory Solid Tumors
1
Oropharyngeal Neoplasms
1
Optic Nerve Glioma
1
Neurologic Manifestations
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Mouth Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Rituximab
47
Cyclophosphamide
26
fludarabine
13
ibrutinib
12
Doxorubicin
11
Vincristine
10
Etoposide
10
Cytarabine
10
Prednisone
9
Bortezomib
9
pembrolizumab
7
fludarabine phosphate
6
Lenalidomide
6
Inotuzumab Ozogamicin
6
obinutuzumab
5
Mycophenolic Acid
5
Melphalan
5
Carmustine
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Tacrolimus
4
Prednisolone
4
Methotrexate
4
Gemcitabine
4
Bendamustine Hydrochloride
4
Antilymphocyte Serum
4
tocilizumab
3
tazemetostat
3
Whole-Body Irradiation
3
Vorinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, B-Cell
×
Valproic Acid
×
Clear all
NCT02144623
2017-03-03
PREVAIL
Lund University Hospital
Phase EARLY_PHASE1
Completed
4 enrolled